Pharmacogenomics of drugs affecting the cardiovascular system

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 590-599

  Siest, Gérard ^a   Ferrari, Luc ^a   Accaoui, Marie José ^a   Batt, Anne Marie ^a   Visvikis, Sophie ^a  

^a INSERM   (France)

Author keywords

2 receptors; ABC transporter; Angiotensin converting enzyme; Apolipoprotein E; Cardiovascular; Genomics; N acetyltransferase; P450

Indexed keywords

ABC TRANSPORTER; AMIODARONE; ANTIARRHYTHMIC AGENT; APOLIPOPROTEIN E; ATORVASTATIN; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; FELODIPINE; GLUTATHIONE TRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LERCANIDIPINE; MEVINOLIN; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PROPAFENONE; QUINIDINE; SIMVASTATIN; STEROL; UNINDEXED DRUG; VERAPAMIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSFORMATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN GENETICS; HUMAN GENOME; HYPERTENSION; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN POLYMORPHISM; PROTEIN TRANSPORT; REVIEW; SIDE EFFECT;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; LIPID METABOLISM; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0038058953     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.089     Document Type: Review

References (70)

1. Licinio J, Wong ML, Pharmacogenomics. The search for individualized therapies. Weinheim: Wiley-VCH, 2002; pp 1-559.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. J Am Med Assoc 1998; 279:1200-5.
3. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369:11-23.
4. Hasler J, Estabrook R, Murray M, Pikuleva I, Waterman M, Capdevila J, et al. Human cytochromes P450. Mol Aspects Med 1999; 20:1-137.
5. Nakagawa K, Ishizaki T. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther 2000; 86:1-28.
6. Daujat M, Pichard L, Fabre I, Pineau T, Fabre G, Bonfils C, et al. Induction protocols for cytochromes P450IIIA in vivo and in primary cultures of animal and human hepatocytes. Methods Enzymol 1991; 206:345-53.
7. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-91.
8. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281:1349-55.
9. Cheng JW. Cytochrome p450-mediated cardiovascular drug interactions. Heart Dis 2000; 2:254-8.
10. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-50.
11. Stefanovic M, Topic E, Ivanisevic AM, Relja M, Korsic M. Genotyping of CYP2D6 in Parkinson's disease. Clin Chem Lab Med 2000; 38:929-34.
12. Sarfarazi M, Stoilov I. Molecular genetics of primary congenital glaucoma. Eye 2000; 14:422-8.
13. Okuyama E, Tomita S, Takeuchi H, Ichikawa Y. A novel mutation in the cytochrome P450(27) (CYP27) gene caused cerebrotendinous xanthomatosis in a Japanese family. J Lipid Res 1996; 37:631-9.
14. Wang J, Freeman DJ, Grundy SM, Levine DM, Guerra R, Cohen JC. Linkage between cholesterol 7-alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest 1998; 101:1283-91.
15. Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, et al. Alterations in the regulation of androgen-sensitive CYP 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 2001, 98:5211-6.
16. Capdevila JH, Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 2001; 285:571-6.
17. King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyltransferases. Curr Drug Metab 2000; 1:143-61.
18. Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38:889-92.
19. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.
20. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-51.
21. Schmitz G, Kaminski WE, Orso E. ABC transporters in cellular lipid trafficking. Curr Opin Lipidol 2000, 11:493-501.
22. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001, 69:278-90.
23. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 2001; 6:835-9.
24. Baron JM, Goh LB, Yao D, Wolf CR, Friedberg T. Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping. J Pharmacol Exp Ther 2001; 296:351-8.
25. Siest G, Schlenck A, Starck M, Vincent-Viry M, Schiele F, Visvikis S. Apolipoprotein E: laboratory determinations and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing, 2nd ed. Washington: AACC Washington Press Publ, 2000:401-40.
26. Vincent-Viry M, Schiele F, Gueguen R, Bohnet K, Visvikis S, Siest G. Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the Stanislas cohort study. Clin Chem 1998; 44:957-65.
27. Miettinen TA, Vanhanen H; Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis 1994; 105:217-26.
28. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT, et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 1994; 35:1965-75.
29. Savolainen MJ, Rantala M, Kervinen K, Jarvi L, Suvanto K, Rantala T, et al. Magnitude of dietary effects on plasma concentration: role of sex and apolipoprotein E phenotype. Atherosclerosis 1991; 186:145-52.
30. Sarkkinen ES, Uusitupa MI, Pietinen P, Aro A, Ahola I, Penttila I, et al. Long-term effects of three fat-modified diets in hypercholesterolemic subjects. Atherosclerosis 1994; 105:9-23.
31. Gylling H, Miettinen TA. Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes. J Lipid Res 1992; 33:1361-71.
32. Sarkkinen E, Korhonen M, Erkkila A, Ebeling T, Uusitupa M. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr 1998; 68:1215-22.
33. Cobb MM, Teitlebaum H, Risch N, Jekel J, Ostfeld A. Influence of dietary fat, apolipoprotein E phenotype, and sex on plasma lipoprotein levels. Circulation 1992; 86:849-57.
34. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC, et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000; 20: 1990-7.
35. Fernandez-Miranda C, Cancelas P, Sanz M, Porres A, Gamez-Gerique J. Influence of apolipoprotein-E phenotypes on postprandial lipoprotein metabolism after three different fat loads. Nutrition 2001; 17:529-33.
36. Ordovas JM, Schaefer EJ. Genetic determinants of plasma lipid response to dietary intervention: the role of the apoA1/C3/A4 gene cluster and the apoE gene. Br J Nutr 2000; 8:127-36.
37. Siest G, Bertrand P, Herbeth B, Vincent-Viry M, Schiele F, Sass C, et al. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin Chem Lab Med 2000; 38:841-52.
38. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990; 38:150-4.
39. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993; 42:895-901.
40. Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolemia. J Intern Med 1991; 230:397-405.
41. Sanllehy C, Casals E, Rodriguez-Villar C, Zambon D, Ojuel J, Ballesta AM, et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 1998; 47:560-65.
42. De Knijff P, Stalenhoef AF, Mol MJ, Gevers Leuven JA, Smit J, Erkelens DW, et al. Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990; 83:89-97.
43. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hypercholesterolemia: prediction of response by baseline lipids, apoE genotype, lipoprotein(a) and insulin. Atherosclerosis 1997; 129:231-9.
44. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999; 143:41-54.
45. Watanabe J, Kobayashi K, Umeda F, Yamauchi T, Mimura K, Nakashima N, et al. Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients. Diabetes Res Clin Pract 1993; 20:21-7.
46. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy. Atherosclerosis 1995; 113:157-66.
47. Berglund L, Wiklund O, Eggertsen G, Olofsson SO, Eriksson M, Linden T, et al. Apolipoprotein E phenotypes in familial hypercholesterolemia: importance for expression of disease and response to therapy. J Intern Med 1993; 233: 173-8.
48. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158:183-93.
49. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101: 1366-71.
50. Kohlmeier M, Salomon, A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. J Nutr 1996; 126:1192-6.
51. Starck M, Schiele F, Herbeth B, Vincent-Viry M, Beaud B, Siest G, et al. Apolipoproteins E and C-III serum concentration in apoB and non-apoB-containing lipoproteins in middle-aged women from the Stanislas cohort: effect of oral contraceptive use and apolipoprotein E common polymorphism. Atherosclerosis 2001; 155:509-16.
52. Tsuda M, Sanada M, Nakagawa H, Kodama I, Sakashita T, Ohama K. Phenotype of apolipoprotein E influences the lipid metabolic response of postmenopausal women to hormone replacement therapy. Maturitas 2001; 38:297-304.
53. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103:792-8.
54. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86-93.
55. Liggett SB: β2-adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 2000; 161:197-201.
56. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, et al. Beta(2)-adrenoreceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36:371-5.
57. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18:45-8.
58. Schunkert H, Hense HW, Doring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998; 32:510-3.
59. Hegele RA, Harris SB, Hanley AJ, Cao H, Zimman B. G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. Hypertension 1998; 32:688-92.
60. Soubrier F. Polymorphism of the renin-angiotensin-aldosterone system: molecular and epidemiogenetic aspects. Néphrologie 1998; 19:377-84.
61. Ueda S, Meredith PA, Morton JJ, Connell JMC, Elliott HL. ACE (I/C) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148-53.
62. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-97.
63. Chamberlain JC, Joubert PH. Opportunities and strategies for introducing pharmacogenetics into early drug development. Drug Discov Today 2001; 6:569-74.
64. Tomlinson B. Pharmacokinetic and pharmacodynamic responses to cardiovascular drugs in Asians. Acta Pharmacol Sin 1998; 19:12-3.
65. Sanders R. Mining the Swedish clinical archives to develop pharmacogenomics tests. Mol Diagn 1999; 4:319-25.
66. Roses AD. Pharmacogenetics and the practice of medecine. Nature 2000; 405:857-65.
67. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nature 2001; 2:228-31.
68. Issa AM. Ethical considerations in clinical pharmacogenomics research. TIPS 2000; 21:247-9.
69. Coats AJS. Pharmacogenomics: hope or hype? Int J Cardiol 2000; 76:1-3.
70. Robertson JA. Consent and privacy in pharmacogenetic testing. Nat Genet 2001; 28:207-9.